ArticleMicrobial biotechnology2022
Hyperproduction of PHA copolymers containing high fractions of 4-hydroxybutyrate (4HB) by outer membrane-defected Halomonas bluephagenesis grown in bioreactors.
Article in Microbial biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Biodegradable Polyhydroxyalkanoates as Advanced Antimicrobial Biomaterials: A Review.Biotechnology and bioengineering · 2026Review
- Synthesis of tunable copolymers of 3-hydroxybutyrate and 3-hydroxyvalerate by engineeredSynthetic and systems biotechnology · 2026Article
- Halomonas sp. MC140, a polyhydroxyalkanoate (PHA) producer isolated from the Arctic environment.Scientific reports · 2025Article
- Production of polyhydroxyalkanoate (PHA) biopolymer from crop residue using bacteria as an alternative to plastics: a review.RSC advances · 2025Review
- Natural Polyhydroxyalkanoates-An Overview of Bacterial Production Methods.Molecules (Basel, Switzerland) · 2024Review
- Genetic engineering of low-temperature polyhydroxyalkanoate production by Acidovorax sp. A1169, a psychrophile isolated from a subglacial outflow.Extremophiles : life under extreme conditions · 2023Article
- Construction of cell factory through combinatorial metabolic engineering for efficient production of itaconic acid.Microbial cell factories · 2022Article
- Adaptive Laboratory Evolution ofMolecules (Basel, Switzerland) · 2022Article
- Hyperproduction of PHA copolymers containing high fractions of 4-hydroxybutyrate (4HB) by outer membrane-defected Halomonas bluephagenesis grown in bioreactors.Microbial biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial outer membrane (OM) is a self-protective and permeable barrier, while having many non-negligible negative effects in industrial biotechnology. Our previous studies revealed enhanced properties of Halomonas bluephagenesis based on positive cellular properties by OM defects. This study further expands the OM defect on membrane compactness by completely deleting two secondary acyltransferases for lipid A modification in H. bluephagenesis, LpxL and LpxM, and found more significant advantages than that of the previous lpxL mutant. Deletions on LpxL and LpxM accelerated poly(3-hydroxybutyrate) (PHB) production by H. bluephagenesis WZY229, leading to a 37% increase in PHB accumulation and 84-folds reduced endotoxin production. Enhanced membrane permeability accelerates the diffusion of γ-butyrolactone, allowing H. bluephagenesis WZY254 derived from H. bluephagenesis WZY229 to produce 82wt% poly(3-hydroxybutyrate-co-23mol%4-hydroxybutyrate) (P(3HB-co-23mol%4HB)) in shake flasks, showing increases of 102% and 307% in P(3HB-co-4HB) production and 4HB accumulation, respectively. The 4HB molar fraction in copolymer can be elevated to 32 mol% in the presence of more γ-butyrolactone. In a 7-l bioreactor fed-batch fermentation, H. bluephagenesis WZY254 supported a 84 g l
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.